Hydrochlorothiazide Eg (Hydrochlorothiazide)

Hydrochlorothiazide EG is indicated for conditions where reduction of excess fluid or control of high blood pressure is required. It is frequently employed in the following clinical situations:

• Hypertension (essential or secondary) requiring diuretic therapy.
• Edema associated with congestive heart failure.
• Fluid retention due to liver cirrhosis.
• Nephrotic syndrome–related swelling.
• Adjunctive treatment for hypercalciuria or calcium‑containing kidney stones.

• Hydrochlorothiazide acts on the distal convoluted tubule of the nephron, where it blocks the Na⁺/Cl⁻ symporter. By inhibiting this transporter, the drug reduces sodium and chloride reabsorption, leading to increased excretion of sodium, chloride, and water. The resulting decrease in extracellular fluid volume lowers cardiac output and peripheral vascular resistance, contributing to blood pressure reduction. The modest potassium loss that accompanies the diuretic effect is a characteristic pharmacodynamic consequence.

Like all thiazide diuretics, Hydrochlorothiazide EG may cause a range of adverse reactions, most of which are dose‑related and reversible.

Common

• Increased urination, especially during the first few days of therapy.
• Mild electrolyte changes such as low potassium or sodium.
• Slight rise in blood glucose levels.
• Transient dizziness or headache.

Serious

• Severe dehydration or electrolyte imbalance (e.g., hyponatremia, hypokalemia).
• Acute gout attacks triggered by elevated uric acid.
• Allergic reactions including rash, itching, or angioedema.
• Pancreatitis or hepatic dysfunction (rare).

Before initiating Hydrochlorothiazide EG, clinicians should evaluate patient history and laboratory values to minimize risk of complications.

• Assess renal function; avoid use in severe renal impairment.
• Monitor serum electrolytes (potassium, sodium, magnesium) regularly.
• Caution in patients with a history of gout or hyperuricemia.
• Evaluate blood glucose in diabetic individuals, as thiazides may raise glucose.
• Review concurrent use of other diuretics or antihypertensives to prevent excessive volume loss.
• Consider pregnancy status; safety data are limited.
• Avoid abrupt discontinuation, which can cause fluid retention rebound.

Hydrochlorothiazide EG can alter the pharmacokinetics or pharmacodynamics of several medicines; awareness of key interactions helps maintain therapeutic safety.

Avoid

• Lithium, because thiazides reduce renal clearance and may cause toxicity.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs), which can blunt diuretic efficacy and worsen renal function.
• ACE inhibitors or ARBs combined with high‑dose thiazide without monitoring, increasing risk of hyperkalemia.

Use with caution

• Anticoagulants (e.g., warfarin), as fluid shifts may affect INR.
• Antidiabetic agents, since blood glucose may rise.
• Corticosteroids, which can enhance potassium loss.
• Digoxin, due to potential electrolyte disturbances affecting cardiac conduction.